Thiarabine
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2010 (NCT01139151)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- DNA polymerase nuINHIBITOR
POLN inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Nc1ccn([C@@H]2S[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1- Mol. weight
- 259.29 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1631221 ↗
Also known as
- 4'-thio-arabinofuranosylcytosine
- 4'-thio-beta-d-arabinofuranosylcytosine
- osi-7836
- osi-7836
- thiarabine
- thiarabine
- thiarabine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01139151 | Phase 1 | Aug 1, 2010 | Access Pharmaceuticals, Inc., University of Texas at Houston |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Access Pharmaceuticals, Inc. | For profit | 1 | 0 | 1 | 2010 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2010 |
2 organizations
Page 1 / 1